General
Preferred name
ELAFIBRANOR
Synonyms
GFT505 ()
GFT-505 ()
Iqirvo ()
IQIRVO ()
P&D ID
PD052543
CAS
824932-88-9
923978-27-2
Tags
available
drug
Drug indication
Type-2 diabetes
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
Drug Status
approved
investigational
Max Phase
4.0
First approval
2024
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA GFT505 is an oral treatment that acts on the 3 sub-types of PPAR (PPARa, PPARg, PPARd) with a preferential action on PPARa. It has a sophisticated mechanism of action. It is able to differentially recruit cofactors to the nuclear receptor, which subsequently lead to differential regulation of genes and biological effect. Therefore, the ability to identify and profile the activity of selective nuclear receptor modulator (SNuRMs) is a powerful approach to select innovative drug candidates with improved efficacy and diminished side effects. These pluripotent and multimodal molecules have significant positive effects on obesity, insulin-resistance and diabetes, atherosclerosis, inflammation, and the lipid triad (increasing of HDL cholesterol, lowering of triglycerides and LDL cholesterol).;
DESCRIPTION Elafibranor (GFT505) is a PPAR¦Á/¦Ä agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis[1].
PRICE 61
DESCRIPTION Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-?? (PPAR-??) and peroxisome proliferator-activated receptor-?? (PPAR-??) with EC50 values of 45 and 175 nM, respectively.
DESCRIPTION Elafibranor (GFT-505) is a PPARα/δ agonist. (GtoPdb)
DESCRIPTION Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively. (TargetMol Bioactive Compound Library)
Compound Sets
14
Axon Medchem Screening Library
2727
Cayman Chemical Bioactives
23508
ChEMBL Approved Drugs
CHEMBL3707395
ChEMBL Drugs
CHEMBL3707395
Drug Repurposing Hub
DrugBank
DB05187
DrugBank Approved Drugs
DB05187
DrugMAP
DM7ZOAE
EUbOPEN Chemogenomics Library
EUB0001147
Guide to Pharmacology
11135
MedChem Express Bioactive Compound Library
HY-16737
ReFrame library
Selleckchem Bioactive Compound Library
elafibranor
TargetMol Bioactive Compound Library
T4408
External IDs
21
Properties
(calculated by RDKit )
Molecular Weight
384.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
2
cLogP
5.16
TPSA
63.6
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
6.0
QED
0.41
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PPAR
PPARα
PPARδ
PPAR-¦Á
PPAR-¦Ä
PPAR??,PPAR??
PPARA, PPARD, PPARG
PPAR a/d agonist
MOA
PPAR agonist
PPAR receptor agonist
Pathway
DNA Damage/DNA Repair
Metabolism
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Recommended Cell Concentration
1 uM
Source data